4.6 (790) In stock
Frequency of driver mutations in lung adenocarcinoma A. and lung
AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
Frontiers Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer
Uncommon Oncogenic Drivers in NSCLC - (ILCN/WCLC)
media.springer/m685/springer-static/imag
AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
Recombinant Anti-LTK antibody [EPR5175(2)] (ab129155)
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. - Abstract - Europe PMC
Electropherogram showing Sanger sequencing of the CLIP1-LTK fusion
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. - Abstract - Europe PMC
Nature里程碑：非小细胞肺癌新靶点——CLIP1-LTK
Department of Thoracic Oncology National Cancer Center Hospital East
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
2022肺癌靶标热点追击，ERRα/LTK/EMSY初露锋芒-源井生物- 知乎
